Skip to main content

GeoVax Labs, Inc.

Monday, February 26, 2024
Infectious Diseases
GeoVax is developing novel therapies and vaccines for solid tumor cancers and infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). GEO-CM04S1 is also being evaluated in a Phase 2 clinical trial as a more robust, durable COVID-19 booster in healthy patients who previously received the mRNA vaccines.
David Dodd, Chairman & CEO - GeoVax Labs, Inc.




United States


CEO/Top Company Official

David Dodd

Lead Product in Development

GEO-CM04S1 - Next-Generation Covid vaccine. Gedeptin - Therapy for solid tumor cancers

Development Phase of Primary Product

Phase II

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.